Entera Bio Q1 net loss $2.2M vs $3.8M YoY; cash $10.7M into Q3 2024

Entera Bio Ltd.

2023-Q1 EPS reported $0.08

Net loss of $2.2M, $0.08 per share, compared to $3.8M, $0.13 per share in Q1 2022.
Cash and equivalents $10.7M as of Mar 31, 2023; expects cash to fund ops into Q3 2024.
R&D expenses $0.9M (down 47% YoY); G&A expenses $1.3M (down 41% YoY).
Plans to initiate PK study of oral PTH(1-34) for hypoparathyroidism H1 2023, topline H2 2023.
Amgen research collaboration discontinued by mutual agreement after 4+ years.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entera Bio Ltd. reported first quarter ended March 31, 2023 results: net income Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023, EPS $0.08 per ordinary share (basic and diluted).

Period: first quarter ended March 31, 2023
Net income: Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023
EPS: $0.08 per ordinary share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss was $2.2 million, or $0.08 per ordinary share (basic and diluted), for the quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-23-001714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.